Display options
Cite
Hassan M, Selimovic D, Hannig M, et al. Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World J Exp Med. 2015;5(4):206-17doi: 10.5493/wjem.v5.i4.206.
Hassan, M., Selimovic, D., Hannig, M., Haikel, Y., Brodell, R. T., & Megahed, M. (2015). Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World journal of experimental medicine, 5(4), 206-17. https://doi.org/10.5493/wjem.v5.i4.206
Hassan, Mohamed, et al. "Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment." World journal of experimental medicine vol. 5,4 (2015): 206-17. doi: https://doi.org/10.5493/wjem.v5.i4.206
Hassan M, Selimovic D, Hannig M, Haikel Y, Brodell RT, Megahed M. Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World J Exp Med. 2015 Nov 20;5(4):206-17. doi: 10.5493/wjem.v5.i4.206. eCollection 2015 Nov 20. PMID: 26618107; PMCID: PMC4655250.
Copy Download .nbib Format: NLM
Share it on

World J Exp Med. 2015 Nov 20;5(4):206-17. doi: 10.5493/wjem.v5.i4.206. eCollection 2015 Nov 20.

Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment.

World journal of experimental medicine

Mohamed Hassan, Denis Selimovic, Matthias Hannig, Youssef Haikel, Robert T Brodell, Mossaad Megahed

Affiliations

  1. Mohamed Hassan, Denis Selimovic, Matthias Hannig, Clinic of Operative Dentistry, Periodontology and Preventive Dentistry, University Hospital, Saarland University, D-66421 Homburg/Saar, Germany.

PMID: 26618107 PMCID: PMC4655250 DOI: 10.5493/wjem.v5.i4.206

Abstract

Melanoma is the most aggressive form of skin cancer. Disrupted intracellular signaling pathways are responsible for melanoma's extraordinary resistance to current chemotherapeutic modalities. The pathophysiologic basis for resistance to both chemo- and radiation therapy is rooted in altered genetic and epigenetic mechanisms that, in turn, result in the impairing of cell death machinery and/or excessive activation of cell growth and survival-dependent pathways. Although most current melanoma therapies target mitochondrial dysregulation, there is increasing evidence that endoplasmic reticulum (ER) stress-associated pathways play a role in the potentiation, initiation and maintenance of cell death machinery and autophagy. This review focuses on the reliability of ER-associated pathways as therapeutic targets for melanoma treatment.

Keywords: Apoptosis; Autophagy; Chemotherapy; Endoplasmic reticulum; Melanoma; Signaling pathways

References

  1. Pharmacol Rev. 2011 Sep;63(3):700-27 - PubMed
  2. Expert Opin Pharmacother. 2003 Dec;4(12):2205-11 - PubMed
  3. Oncogene. 2015 Oct 16;34(42):5363-71 - PubMed
  4. Br J Dermatol. 2015 Jan;172(1):239-43 - PubMed
  5. Surg Clin North Am. 2003 Feb;83(1):109-56 - PubMed
  6. J Pharmacol Exp Ther. 2005 Dec;315 (3):1403-11 - PubMed
  7. EMBO Rep. 2009 Mar;10 (3):285-92 - PubMed
  8. Cancer Res. 2006 Oct 1;66(19):9483-91 - PubMed
  9. Oncogene. 2012 May 17;31(20):2580-92 - PubMed
  10. Int Rev Cell Mol Biol. 2013;301:215-90 - PubMed
  11. Clin Cancer Res. 2011 Apr 15;17(8):2216-26 - PubMed
  12. Sci Signal. 2013 Jan 29;6(260):ra7 - PubMed
  13. Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11807-14 - PubMed
  14. Mol Oncol. 2008 Apr;1(4):395-405 - PubMed
  15. Melanoma Res. 2014 Dec;24(6):577-83 - PubMed
  16. J Biol Chem. 2006 Jul 7;281(27):18691-706 - PubMed
  17. J Cancer Res Clin Oncol. 2013 Sep;139(9):1551-62 - PubMed
  18. Cancer Lett. 2014 Feb 1;343 (1):123-33 - PubMed
  19. PLoS One. 2011;6(10 ):e26420 - PubMed
  20. PLoS One. 2013 Sep 27;8(9):e75280 - PubMed
  21. Anal Bioanal Chem. 2015 Jul;407(18):5343-51 - PubMed
  22. Lancet Oncol. 2014 Apr;15(4):436-44 - PubMed
  23. Int J Oncol. 2015 Mar;46(3):1286-94 - PubMed
  24. Biochem Biophys Res Commun. 2001 Dec 7;289(3):718-24 - PubMed
  25. J Ethnopharmacol. 2013 Jul 9;148(2):544-55 - PubMed
  26. Pigment Cell Melanoma Res. 2014 May;27(3):465-78 - PubMed
  27. Hematol Oncol Clin North Am. 2009 Jun;23(3):599-618, x - PubMed
  28. J Neurosci. 2010 Dec 15;30(50):16938-48 - PubMed
  29. PLoS One. 2013 Dec 19;8(12):e84073 - PubMed
  30. Oncotarget. 2015 May 30;6(15):13278-94 - PubMed
  31. J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8 - PubMed
  32. PLoS One. 2012;7(7):e40439 - PubMed
  33. Apoptosis. 2013 Aug;18(8):980-97 - PubMed
  34. PLoS One. 2012;7(10 ):e48235 - PubMed
  35. Arch Biochem Biophys. 2014 Dec 1;563:108-17 - PubMed
  36. J Biol Chem. 2013 Jan 18;288(3):1691-5 - PubMed
  37. Br J Radiol. 2011 Dec;84(1008):1083-90 - PubMed
  38. Biochem Biophys Res Commun. 2007 Aug 3;359(3):778-83 - PubMed
  39. J Clin Invest. 2014 Mar;124(3):1406-17 - PubMed
  40. Mar Drugs. 2012 Aug;10(8):1883-98 - PubMed
  41. Exp Cell Res. 2015 Jun 10;334(2):207-18 - PubMed
  42. PLoS One. 2014 Feb 20;9(2):e89218 - PubMed
  43. Carcinogenesis. 2006 Sep;27(9):1812-27 - PubMed
  44. J Clin Invest. 2009 Oct;119(10):2925-41 - PubMed
  45. Gynecol Oncol. 2013 Feb;128(2):383-90 - PubMed
  46. J Invest Dermatol. 2004 Feb;122(2):337-41 - PubMed
  47. J Cell Physiol. 2011 Mar;226(3):720-8 - PubMed
  48. PLoS One. 2014 Jul 07;9(7):e101579 - PubMed
  49. PLoS One. 2014 Mar 19;9(3):e92627 - PubMed
  50. Cancer Res. 2007 Oct 15;67(20):9750-61 - PubMed
  51. J Invest Dermatol. 2010 Jun;130(6):1657-67 - PubMed
  52. Oncogene. 2016 Feb 25;35(8):1015-24 - PubMed
  53. Autophagy. 2014 Jun;10 (6):1120-36 - PubMed
  54. Cell Signal. 2013 Nov;25(11):2136-46 - PubMed
  55. Tumori. 2001 Jul-Aug;87(4):219-22 - PubMed
  56. Am J Dermatopathol. 1999 Feb;21(1):28-30 - PubMed
  57. J Dtsch Dermatol Ges. 2015 Apr;13(4):308-15 - PubMed
  58. Mol Med Rep. 2014 Aug;10 (2):1103-7 - PubMed
  59. Cancer Biol Ther. 2011 Jan 15;11(2):216-28 - PubMed
  60. Cancer Treat Rev. 2015 Jun;41(6):519-26 - PubMed
  61. Apoptosis. 2008 Jul;13(7):904-14 - PubMed
  62. Blood. 2012 Oct 25;120(17):3519-29 - PubMed
  63. Cell Death Dis. 2010 Oct 21;1:e87 - PubMed
  64. Cell Signal. 2013 Jan;25(1):308-18 - PubMed
  65. Anticancer Res. 2014 Jun;34(6):3197-203 - PubMed
  66. EMBO Rep. 2010 Jul;11(7):515-21 - PubMed
  67. Cancer Res. 2009 Jul 1;69(13):5458-66 - PubMed
  68. Melanoma Res. 2001 Aug;11(4):411-5 - PubMed
  69. Biochem Pharmacol. 2013 May 15;85(10 ):1463-77 - PubMed
  70. Ann Oncol. 2014 Jul;25(7):1437-41 - PubMed
  71. Cancer Res Treat. 2015 Oct;47(4):781-9 - PubMed
  72. Cell Stress Chaperones. 2010 Sep;15(5):497-508 - PubMed
  73. Acta Dermatovenerol Croat. 2012;20(3):191-6 - PubMed
  74. Molecules. 2014 Aug 06;19(8):11679-721 - PubMed
  75. J Invest Dermatol. 2014 Feb;134(2):488-97 - PubMed
  76. Mol Ther. 2015 May;23(5):931-42 - PubMed
  77. BMC Cancer. 2005 Jun 03;5:58 - PubMed
  78. Clin Cancer Res. 2010 Jan 1;16(1):348-57 - PubMed
  79. Melanoma Res. 2014 Oct;24(5):496-500 - PubMed
  80. Br J Pharmacol. 2013 Oct;170(4):822-34 - PubMed
  81. PLoS One. 2013;8(1):e55096 - PubMed
  82. Blood. 2006 Jun 15;107(12):4907-16 - PubMed
  83. Am J Clin Oncol. 2015 Feb;38(1):119-25 - PubMed
  84. Anticancer Res. 2015 Feb;35(2):1105-13 - PubMed
  85. Invest New Drugs. 2013 Aug;31(4):937-42 - PubMed
  86. J Transl Med. 2012 Jan 25;10 :15 - PubMed
  87. Proteomics. 2010 Nov;10(22):4040-52 - PubMed
  88. J Agric Food Chem. 2013 Nov 20;61(46):11008-15 - PubMed
  89. Diabetologia. 2010 Jun;53(6):1120-30 - PubMed
  90. Int J Cancer. 2011 Nov 1;129(9):2297-303 - PubMed
  91. Autophagy. 2012 Aug;8(8):1185-96 - PubMed
  92. Exp Cell Res. 2009 Nov 15;315 (19):3325-35 - PubMed
  93. Cell Signal. 2014 Feb;26(2):287-94 - PubMed
  94. Carcinogenesis. 2011 Aug;32(8):1268-78 - PubMed
  95. J Invest Dermatol. 2010 Sep;130(9):2250-8 - PubMed
  96. Mol Cancer Ther. 2003 Aug;2(8):753-63 - PubMed
  97. Semin Cancer Biol. 2013 Oct;23(5):352-60 - PubMed
  98. Sci Signal. 2015 Mar 10;8(367):ra27 - PubMed
  99. Pigment Cell Melanoma Res. 2014 Jul;27(4):525-39 - PubMed
  100. Cancer Lett. 2015 Feb 1;357(1):83-104 - PubMed
  101. PLoS One. 2013;8(1):e55509 - PubMed
  102. Cancer Res. 2007 Jun 15;67(12):5880-8 - PubMed
  103. Oncogene. 2013 Feb 14;32(7):805-18 - PubMed
  104. Melanoma Res. 2014 Oct;24(5):501-3 - PubMed
  105. Int J Oncol. 2012 Dec;41(6):2029-37 - PubMed
  106. Mol Pharmacol. 2015 Aug;88(2):304-15 - PubMed
  107. Cell Signal. 2008 Feb;20(2):311-22 - PubMed
  108. Genes (Basel). 2013 Jul 01;4(3):306-33 - PubMed
  109. Oncogene. 2008 Jul 31;27(33):4557-68 - PubMed
  110. Oncogene. 2006 Jun 8;25(24):3357-64 - PubMed
  111. Cancer Chemother Pharmacol. 2013 Feb;71(2):441-55 - PubMed
  112. Cancer Res. 2005 Dec 15;65(24):11658-66 - PubMed
  113. Toxicol Lett. 2014 Aug 4;228(3):248-59 - PubMed
  114. Ann Pharmacother. 2013 Apr;47(4):519-26 - PubMed
  115. J Cancer Res Clin Oncol. 2014 Jun;140(6):921-35 - PubMed
  116. Pigment Cell Melanoma Res. 2010 Oct;23(5):675-82 - PubMed
  117. Br J Cancer. 2013 Jul 23;109(2):433-43 - PubMed
  118. Neurobiol Dis. 2010 Oct;40(1):12-20 - PubMed
  119. Cell Death Dis. 2014 May 29;5:e1270 - PubMed
  120. Sci Rep. 2014 Jul 01;4:5510 - PubMed
  121. Int J Oncol. 2011 Jan;38(1):241-7 - PubMed
  122. Cancer Chemother Pharmacol. 2013 Jun;71(6):1567-76 - PubMed
  123. J Neurosci. 2001 Dec 15;21(24):9549-60 - PubMed
  124. Apoptosis. 2008 Dec;13(12):1505-12 - PubMed
  125. Neoplasia. 2009 Sep;11(9):945-55 - PubMed
  126. J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90 - PubMed

Publication Types